You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for Patent: 8,299,078


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,299,078 protect, and when does it expire?

Patent 8,299,078 protects FOLOTYN and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 8,299,078
Title:Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
Abstract: T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m.sup.2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m.sup.2 per dose.
Inventor(s): O'Connor; Owen A. (Scarsdale, NY), Sirotnak; Francis M. (Hampton Bays, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:12/603,117
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,299,078
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,299,078: A Comprehensive Analysis

Introduction

Patents are a crucial component of intellectual property law, providing inventors and innovators with exclusive rights to their inventions. The United States Patent and Trademark Office (USPTO) is responsible for granting these patents, ensuring that the inventions meet the criteria of novelty, non-obviousness, and usefulness. This article delves into the specifics of United States Patent 8,299,078, analyzing its scope, claims, and the broader patent landscape.

What is United States Patent 8,299,078?

To begin with, it is essential to identify the patent in question. However, since the specific details of Patent 8,299,078 are not provided in the sources, we will discuss the general process and key elements involved in understanding any patent.

Patent Scope and Claims

Definition of Patent Scope

The scope of a patent refers to the extent of protection granted to the inventor. It is defined by the claims section of the patent, which outlines the specific features and limitations of the invention[3].

Understanding Patent Claims

Patent claims are the heart of a patent, as they define the boundaries of the invention. These claims must be clear, concise, and supported by the description provided in the patent specification. The USPTO's Patent Claims Research Dataset provides detailed information on claims from US patents, including claim-level statistics and document-level statistics, which can help in analyzing the scope of a patent[3].

Types of Claims

Independent Claims

Independent claims stand alone and do not refer to any other claims. They define the invention in its broadest sense.

Dependent Claims

Dependent claims refer back to an independent claim or another dependent claim, narrowing down the scope of the invention.

Method Claims

Method claims describe the steps involved in performing a process.

Apparatus Claims

Apparatus claims describe the physical components of an invention.

Analyzing the Claims of Patent 8,299,078

Without the specific text of Patent 8,299,078, we can't analyze its claims directly. However, here are the steps you would typically follow:

  1. Identify Independent Claims: These claims provide the broadest definition of the invention.
  2. Analyze Dependent Claims: These claims narrow down the scope by adding specific features or limitations.
  3. Understand Method and Apparatus Claims: Determine if the patent includes method claims, apparatus claims, or both.

Patent Landscape and Related Patents

Continuations and Continuations-in-Part

Patents can be part of a larger family, including continuations and continuations-in-part. These related patents can affect the scope and validity of the original patent. For example, in the case of In re Cellect, multiple patents were part of the same family, and the obviousness-type double patenting (ODP) analysis was crucial in determining their validity[1].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents an inventor from securing a second, later-expiring patent for an invention that is not significantly different from an earlier patent. This doctrine is particularly relevant when dealing with continuations and continuations-in-part[1].

Patent Term Adjustment (PTA) and Terminal Disclaimers

Patent Term Adjustment

PTA is granted to compensate for delays in the patent prosecution process. However, as seen in In re Cellect, PTA does not extend the term of a patent past the date of a terminal disclaimer. This means that even if a patent receives PTA, it cannot expire later than the terminal disclaimer date[1].

Terminal Disclaimers

Terminal disclaimers are used to overcome ODP rejections by ensuring that the later patent does not extend beyond the expiration date of the earlier patent. This is a critical consideration in managing patent portfolios and ensuring compliance with patent laws[1].

Economic and Legal Implications

Economic Impact

Patents have significant economic implications, as they can provide a competitive edge and protect investments in research and development. The probability of receiving a US patent varies based on several factors, including the technology field and the entity size of the applicant[4].

Legal Considerations

The legal landscape surrounding patents is complex and evolving. For instance, the discussion around a potential small claims patent court highlights the need for more accessible and efficient dispute resolution mechanisms for patent holders[5].

Industry Expert Insights

Industry experts and legal practitioners play a crucial role in shaping patent policy and practice. For example, the Administrative Conference of the United States (ACUS) study on a small claims patent court involved a consultative group of experts who provided insights on the feasibility and structure of such a court[5].

Statistics and Trends

Patent Application and Grant Rates

The USPTO's data shows that the probability of receiving a US patent varies significantly based on the technology field and other application characteristics. For instance, utility patent applications filed between 1996 and 2005 had varying success rates depending on the field and entity size[4].

Patent Scope Measurements

The USPTO's Patent Claims Research Dataset provides detailed statistics on patent scope, including newly-developed measures of patent scope. These measurements help in understanding the breadth and depth of patent protection[3].

Key Takeaways

  • Patent Scope: Defined by the claims section, it outlines the specific features and limitations of the invention.
  • Claims Analysis: Independent and dependent claims, as well as method and apparatus claims, are crucial in understanding the patent.
  • Related Patents: Continuations and continuations-in-part can affect the validity and scope of the original patent.
  • ODP and PTA: Obviousness-type double patenting and patent term adjustment are critical in managing patent portfolios.
  • Economic and Legal Implications: Patents have significant economic and legal implications, including competitive advantages and compliance with patent laws.

FAQs

What is the purpose of patent claims?

Patent claims define the boundaries of the invention and specify what is protected by the patent.

How does obviousness-type double patenting (ODP) affect patents?

ODP prevents an inventor from securing a second, later-expiring patent for an invention that is not significantly different from an earlier patent.

What is Patent Term Adjustment (PTA)?

PTA is granted to compensate for delays in the patent prosecution process, but it does not extend the term of a patent past the date of a terminal disclaimer.

Why are terminal disclaimers important?

Terminal disclaimers are used to overcome ODP rejections by ensuring that the later patent does not extend beyond the expiration date of the earlier patent.

How does the USPTO's Patent Claims Research Dataset help in analyzing patents?

The dataset provides detailed information on claims from US patents, including claim-level statistics and document-level statistics, which help in analyzing the scope and breadth of patent protection.

Sources

  1. In re Cellect, LLC, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. U.S. Patent and Trademark Office (USPTO), USAGov.
  3. Patent Claims Research Dataset, USPTO.
  4. What Is the Probability of Receiving a US Patent?, YJOLT.
  5. U.S. Patent Small Claims Court, Administrative Conference of the United States.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,299,078

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acrotech Biopharma FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-001 Sep 24, 2009 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA ⤷  Subscribe
Acrotech Biopharma FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-002 Sep 24, 2009 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.